Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled Study

被引:93
作者
Brock, Gerald [1 ]
Heiselman, Darell [2 ]
Maggi, Mario [3 ]
Kim, Sae Woong [4 ]
Rodriguez Vallejo, Jose M. [5 ]
Behre, Hermann M. [6 ]
McGettigan, John [7 ]
Dowsett, Sherie A. [2 ]
Hayes, Risa P. [2 ]
Knorr, Jack [2 ]
Ni, Xiao [2 ]
Kinchen, Kraig [2 ]
机构
[1] Univ Western Ontario, Dept Surg, London, ON N6A 3K7, Canada
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Univ Florence, Dept Clin Physiopathol, Florence, Italy
[4] Catholic Univ Korea, Dept Urol, Seoul St Marys Hosp, Seoul, South Korea
[5] Hosp Infanta Leonor, Urol Serv, Madrid, Spain
[6] Univ Hosp Halle Saale, Ctr Reprod Med & Androl, Halle, Germany
[7] Qual Life Med & Res Ctr, Tucson, AZ USA
关键词
testes; hypogonadism; testosterone; treatment outcome; questionnaires; GLOBAL IMPRESSION; BODY-COMPOSITION; GEL; METAANALYSIS; QUESTIONNAIRES; REPLACEMENT; VALIDATION; SYMPTOMS; EFFICACY; THERAPY;
D O I
10.1016/j.juro.2015.10.083
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
Purpose: We determined the effect of testosterone solution 2% on total testosterone level and the 2 symptoms of hypogonadism, sex drive and energy level. Materials and Methods: This was a randomized, multicenter, double-blind, placebo controlled, 16-week study to compare the effect of testosterone and placebo on the proportion of men with a testosterone level within the normal range (300 to 1,050 ng/dl) upon treatment completion. We also assessed the impact of testosterone on sex drive and energy level measured using SAID (Sexual Arousal, Interest and Drive scale) and HED (Hypogonadism Energy Diary), respectively. A total of 715 males 18 years old or older with total testosterone less than 300 ng/dl and at least 1 symptom of testosterone deficiency (decreased energy and/or decreased sexual drive) were randomized to 60 mg topical testosterone solution 2% or placebo once daily. Results: Of study completers 73% in the testosterone vs 15% in the placebo group had a testosterone level within the normal range at study end point (p < 0.001). Participants assigned to testosterone showed greater baseline to end point improvement in SAID scores (low sex drive subset p < 0.001 vs placebo) and HED scores (low energy subset p = 0.02 vs placebo, not significant at prespecified p < 0.01). No major adverse cardiovascular or venous thrombotic events were reported in the testosterone group. The incidence of increased hematocrit was higher with testosterone vs placebo (p = 0.04). Conclusions: Once daily testosterone solution 2% for 12 weeks was efficacious in restoring normal testosterone levels and improving sexual drive in hypogonadal men. Improvement was also seen in energy levels on HED though not at the prespecified p < 0.01. No new safety signals were identified.
引用
收藏
页码:699 / 705
页数:7
相关论文
共 29 条
[1]
Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone [J].
Beggs, Luke A. ;
Yarrow, Joshua F. ;
Conover, Christine F. ;
Meuleman, John R. ;
Beck, Darren T. ;
Morrow, Matthew ;
Zou, Baiming ;
Shuster, Jonathan J. ;
Borst, Stephen E. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2014, 307 (05) :E456-E461
[2]
Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests [J].
Bretz, Frank ;
Posch, Martin ;
Glimm, Ekkehard ;
Klinglmueller, Florian ;
Maurer, Willi ;
Rohmeyer, Kornelius .
BIOMETRICAL JOURNAL, 2011, 53 (06) :894-913
[3]
Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials [J].
Calof, OM ;
Singh, AB ;
Lee, ML ;
Kenny, AM ;
Urban, RJ ;
Tenover, JL ;
Bhasin, S .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2005, 60 (11) :1451-1457
[4]
Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis [J].
Corona, Giovanni ;
Maseroli, Elisa ;
Rastrelli, Giulia ;
Isidori, Andrea M. ;
Sforza, Alessandra ;
Mannucci, Edoardo ;
Maggi, Mario .
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (10) :1327-1351
[5]
Testosterone Supplementation and Sexual Function: A Meta-Analysis Study [J].
Corona, Giovanni ;
Isidori, Andrea M. ;
Buvat, Jaques ;
Aversa, Antonio ;
Rastrelli, Giulia ;
Hackett, Geoff ;
Rochira, Vincenzo ;
Sforza, Alessandra ;
Lenzi, Andrea ;
Mannucci, Edoardo ;
Maggi, Mario .
JOURNAL OF SEXUAL MEDICINE, 2014, 11 (06) :1577-1592
[6]
Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men [J].
Dobs, AS ;
Meikle, AW ;
Arver, S ;
Sanders, SW ;
Caramelli, KE ;
Mazer, NA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) :3469-3478
[7]
Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men [J].
Finkle, William D. ;
Greenland, Sander ;
Ridgeway, Gregory K. ;
Adams, John L. ;
Frasco, Melissa A. ;
Cook, Michael B. ;
Fraumeni, Joseph F., Jr. ;
Hoover, Robert N. .
PLOS ONE, 2014, 9 (01)
[8]
[Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) United States Department of Health and Human Services], 2009, GUID IND PAT REP OUT
[9]
Food and Drug Administration Drug Safety Communication, 2015, REQ LAB CHANG INF PO
[10]
Testosterone Replacement Therapy Faces FDA Scrutiny [J].
Garnick, Marc B. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (06) :563-564